- Home
- APPS vs RAPT Comparison
APPS vs RAPT Comparison
Compare APPS & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- RAPT
- Stock Information
- Founded
- APPS N/A
- RAPT 2015
- Country
- APPS United States
- RAPT United States
- Employees
- APPS N/A
- RAPT N/A
- Industry
- APPS Multi-Sector Companies
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- APPS Miscellaneous
- RAPT Health Care
- Exchange
- APPS Nasdaq
- RAPT Nasdaq
- Market Cap
- APPS 562.7M
- RAPT 498.4M
- IPO Year
- APPS N/A
- RAPT 2019
- Fundamental
- Price
- APPS $6.83
- RAPT $29.44
- Analyst Decision
- APPS Buy
- RAPT Buy
- Analyst Count
- APPS 3
- RAPT 7
- Target Price
- APPS $4.83
- RAPT $35.14
- AVG Volume (30 Days)
- APPS 3.4M
- RAPT 337.2K
- Earning Date
- APPS 11-05-2025
- RAPT 11-11-2025
- Dividend Yield
- APPS N/A
- RAPT N/A
- EPS Growth
- APPS N/A
- RAPT N/A
- EPS
- APPS N/A
- RAPT N/A
- Revenue
- APPS $503,443,000.00
- RAPT N/A
- Revenue This Year
- APPS $10.64
- RAPT N/A
- Revenue Next Year
- APPS $11.24
- RAPT N/A
- P/E Ratio
- APPS N/A
- RAPT N/A
- Revenue Growth
- APPS N/A
- RAPT N/A
- 52 Week Low
- APPS $1.18
- RAPT $5.67
- 52 Week High
- APPS $7.77
- RAPT $32.35
- Technical
- Relative Strength Index (RSI)
- APPS 78.26
- RAPT 80.35
- Support Level
- APPS $6.10
- RAPT $26.93
- Resistance Level
- APPS $6.83
- RAPT $32.35
- Average True Range (ATR)
- APPS 0.39
- RAPT 2.56
- MACD
- APPS 0.16
- RAPT 0.36
- Stochastic Oscillator
- APPS 93.42
- RAPT 79.64
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.